Fundraising Fox
Caribou Biosciences
NASDAQ: CRBUBerkeley, US · Founded 2011 · Delaware corporation · 128 employees on LinkedIn · 10 known investors
Find your way into Caribou Biosciences
Sign up to see every warm intro you have to Caribou Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Caribou Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.
Founders & leadership
Caribou Biosciences was founded in 2011 by Jennifer Doudna, Rachel Haurwitz, Martin Jinek, and Andrew May.
Board
Investors · 10
How we know: the VCSheet dataset · Not right? Tell us
How we know: Avego BioScience Capital's portfolio page · Not right? Tell us
How we know: F-Prime Capital's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: LifeSci Venture Partners's portfolio page · Not right? Tell us
How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$141M disclosed across 3 rounds · 2014–2021
▶$115MraisedMar 2021 · 36 investors · BiotechnologyRule 506(b)
- Robert WeisskoffDirector
- Steven B. KannerExecutive Officer
- Natalie R. SacksDirector
- Santhosh PalaniDirector
- Jeffrey Long-McGieDirector
- Rachel E. HaurwitzExecutive Officer, Director
- Jason O'ByrneExecutive Officer
- Barbara G. McClungExecutive Officer
- Offering amount
- $115M
- Amount sold
- $115M
- Sales commissions
- $5.6M
- Placement agents
- SVB Leerink LLC
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedMay 2016 · 11 investors · BiotechnologyRule 506(b)
- Jenny RookeDirector
- Rodolphe BarrangouDirector
- Robert WeisskoffDirector
- Andrew P. MayExecutive Officer
- Rachel E. HaurwitzExecutive Officer, Director
- Barbara G. McClungExecutive Officer
- Un Kwon-CasadoExecutive Officer
- Philip AustinDirector
- Offering amount
- $30.1M
- Amount sold
- $14.5M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$11.5MraisedMar 2015 · 14 investors · BiotechnologyRule 506(b)
- Andrew MayExecutive Officer
- Rodolphe BarrangouDirector
- Rachel HaurwitzExecutive Officer, Director
- Jenny RookeDirector
- Robert WeisskoffDirector
- Offering amount
- $11.5M
- Amount sold
- $11.5M
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Caribou Biosciences went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Caribou Biosciences.
In the news
Frequently asked questions
- What does Caribou Biosciences do?
- Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.
- Who founded Caribou Biosciences?
- Caribou Biosciences was founded by Jennifer Doudna, Rachel Haurwitz, Martin Jinek, Andrew May in 2011.
- Who are Caribou Biosciences's investors?
- Caribou Biosciences's investors include Aliment Capital, Avego BioScience Capital, F-Prime Capital, IA Seed Ventures, LifeSci Venture Partners, Mission Bay Capital, Mission Biocapital, Pontifax AgTech and 2 more.
- How much funding has Caribou Biosciences raised?
- Caribou Biosciences has disclosed $141M raised across 3 rounds.
- Where is Caribou Biosciences headquartered?
- Caribou Biosciences is headquartered in Berkeley, US.